hVIVO plc Phase 1 clinical trial of AGS-v PLUS
31 Julho 2019 - 3:03AM
RNS Non-Regulatory
TIDMHVO
hVIVO plc
31 July 2019
hVIVO plc
("hVIVO" or the "Company")
A Phase 1 clinical trial of AGS-v PLUS a Universal
mosquito-borne diseases vaccine candidate
- AGS-v PLUS was developed by Imutex Limited, hVIVO's 49% joint venture with the SEEK Group
- The trial will be conducted by the National Institutes of
Health (NIH) and will take place at the University of Maryland
School of Medicine
- The study received additional funding from the UK Department
of Health and Social Care, managed by Innovate UK
London, UK, 31 July 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral challenge, confirms that AGS-v
PLUS, an experimental vaccine designed to protect against many
different mosquito-borne diseases, will be tested in a Phase 1
clinical trial by the NIH at the University of Maryland School of
Medicine (NCT04009824). The vaccine, AGS-v PLUS, was developed by
Imutex Limited, hVIVO's 49% joint venture with the SEEK Group. The
study received additional funding from the UK Department of Health
and Social Care, managed by Innovate UK.
AGS-v PLUS is designed to provoke an immune reaction to the
proteins in mosquito saliva, which can carry many different
pathogens, including Zika and Malaria. This clinical trial will
test the vaccine's safety and immunogenicity when given with or
without adjuvant to small groups of healthy volunteers. The vaccine
may also have a mosquito control component-the trial will collect
data on the fertility of mosquitoes which feed on vaccinated
volunteers. The National Institute of Allergy and Infectious
Diseases (NIAID), part of the NIH, previously tested an earlier
version of this vaccine, AGS-v, in a first-in-human trial conducted
in NIAID's Laboratory of Infectious Diseases' Special Clinical
Studies Unit at the NIH Clinical Center in Bethesda, Maryland, and
final results of this trial are expected in due course
(NCT03055000).
Trevor Phillips, Executive Chairman of hVIVO, said: "It is great
to see the relationship with NIH and the University of Maryland
School of Medicine continues as AGS-v PLUS, one of the assets in
our joint venture Imutex, moves into the clinic. We are pleased
that the development of this asset is continuing with NIAID-funded
researchers testing the vaccine and additional funding for the
study by Innovate UK."
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO is pioneering a human-based clinical trial platform to
accelerate drug and vaccine development in respiratory and
infectious diseases. Leveraging human disease models in HRV, RSV,
Flu Asthma and COPD, the hVIVO platform captures disease in motion,
illuminating the entire disease life cycle from healthy to sick and
back to health. Based in the UK, market leader hVIVO has conducted
more than 50 clinical studies and inoculated over 2500
volunteers.
Forward-looking statements
This announcement includes statements that are, or may be deemed
to be, forward-looking statements. These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms anticipates, believes, estimates, expects,
intends, may, plans, projects, should or will, or, in each case,
their negative or other variations or comparable terminology, or by
discussions of strategy, plans, objectives, goals, future events or
intentions. These forward-looking statements include all matters
that are not historical facts. Any forward-looking statements in
this announcement reflect the Group's (or, as the case may be, the
hVIVO directors') current view with respect to future events and
are subject to risks relating to future events and other risks,
uncertainties and assumptions relating to the Group's operations,
results of operations and growth strategy. Investors should
specifically consider the factors identified in this announcement
which could cause actual results to differ before making an
investment decision.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADDGDRSBXBGCG
(END) Dow Jones Newswires
July 31, 2019 02:03 ET (06:03 GMT)
Hvivo (LSE:HVO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Hvivo (LSE:HVO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024